<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696941</url>
  </required_header>
  <id_info>
    <org_study_id>11693</org_study_id>
    <nct_id>NCT02696941</nct_id>
  </id_info>
  <brief_title>SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis</brief_title>
  <acronym>SMASH</acronym>
  <official_title>SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SGLT2 inhibitors have been proven to be effective in several preclinical rodent models of&#xD;
      non-alcoholic fatty liver disease (NAFLD). Using a choline deficient diet to recapitulate&#xD;
      some of the histological features of human non-alcoholic steatohepatitis (NASH), it was found&#xD;
      that 5 weeks of SGLT2 inhibition led to significant reductions in hepatic triglyceride&#xD;
      content and improved markers of liver fibrosis. Similarly, 4 weeks of treatment in obese mice&#xD;
      led to improved glucose tolerance, reduced hepatic steatosis and reduced markers of liver&#xD;
      oxidative stress in a dose dependent manner. These findings corresponded with an improvement&#xD;
      in traditional liver function tests including the aminotransferases (ALT and AST). The widely&#xD;
      used antidiabetic agent metformin has been shown in rodent models to increase hepatic insulin&#xD;
      sensitivity and lower liver fat content which is in contrast to the findings in humans where&#xD;
      metformin increases hepatic insulin sensitivity, reduces body weight but does not decrease&#xD;
      liver fat content. The reason for the discrepancy between the animal and human studies, with&#xD;
      regards to liver fat content remains unclear.&#xD;
&#xD;
      The investigators hypothesise the following:&#xD;
&#xD;
        -  SGLT2 Inhibitors have the potential to decrease lipid accumulation in the liver through&#xD;
           reduced de novo lipogenesis (DNL)&#xD;
&#xD;
        -  There will be no decrease in endogenous lipid synthesis (DNL) with metformin and thus no&#xD;
           change in liver fat content.&#xD;
&#xD;
      There are two arms to this study.&#xD;
&#xD;
        -  Arm 1: x10 participants with poorly controlled type 2 Diabetes (T2DM) who have been&#xD;
           recommended to start an SGLT2 inhibitor called dapagliflozin will be recruited.&#xD;
&#xD;
        -  Arm 2: x13 participants with insulin resistance who have not yet started any diabetic&#xD;
           medication will be recruited and will be prescribed metformin at standard clinical&#xD;
           doses.&#xD;
&#xD;
      The two arms will run in parallel and all participants will undergo identical investigations&#xD;
      before and after 3 months of treatment with either dapagliflozin or metformin. Investigations&#xD;
      will include liver magnetic resonance imaging/spectroscopy, fat biopsy, fat microdialysis&#xD;
      sampling, two-step hyperinsulinaemic euglycaemic clamp, breath sampling and stable glucose&#xD;
      and palmitate isotope infusions.&#xD;
&#xD;
      The investigators aim to show that SGLT2 inhibition decreases liver fat whereas we aim to&#xD;
      demonstrate why liver fat remains unchanged in humans, treated with metformin. These data&#xD;
      will provide the first evidence for the use SGLT2 inhibitors in NAFLD, and will be highly&#xD;
      informative for the design of future clinical studies. Moreover, the data gained from the&#xD;
      metformin arm of the study will provide the first mechanistic evidence in humans of the&#xD;
      effects of metformin on hepatic fatty acid metabolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">April 1, 2018</completion_date>
  <primary_completion_date type="Actual">April 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic steatosis</measure>
    <time_frame>3 months</time_frame>
    <description>Liver fat measured by magnetic resonance imaging / spectroscopy (MRI/S)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% contribution of newly synthesised lipid to circulating triglyceride levels</measure>
    <time_frame>3 months</time_frame>
    <description>deuterated water incorporation into palmitate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global insulin sensitivity</measure>
    <time_frame>3 months</time_frame>
    <description>two-step hyperinsulinaemic-euglycaemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic insulin sensitivity</measure>
    <time_frame>3 months</time_frame>
    <description>two-step hyperinsulinaemic-euglycaemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrabdominal fat</measure>
    <time_frame>3 months</time_frame>
    <description>Intrabdominal fat depot measured at level of L4-L5, visible on liver MRI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with insulin resistance who have not yet started any diabetic medication will be recruited and will be prescribed metformin at standard clinical doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGLT2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with poorly controlled type 2 Diabetes (T2DM) who have been recommended to start an SGLT2 inhibitor will be recruited.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT2 inhibitor</intervention_name>
    <description>SGLT2 inhibitor has been recommended to be started as part of routine clinical care</description>
    <arm_group_label>SGLT2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Arm 1: SGLT2 inhibitors&#xD;
&#xD;
          -  Volunteers with diagnosis of Type 2 Diabetes on oral anti-diabetic therapy at a stable&#xD;
             dose for ≥3 months including one of the following:&#xD;
&#xD;
             i. Metformin monotherapy ii. Sulphonylurea monotherapy iii. Metformin and&#xD;
             Sulphonylurea dual therapy&#xD;
&#xD;
          -  All volunteers will be due to start SGLT2 inhibitor therapy for inadequate glycaemic&#xD;
             control and it will be prescribed according to licensed indications.&#xD;
&#xD;
        Arm 2: metformin&#xD;
&#xD;
        • Insulin resistant treatment naive individuals as defined by fasting insulin and / or&#xD;
        glucose in top 10th percentile&#xD;
&#xD;
        Both arms:&#xD;
&#xD;
          -  Participant is willing and able to give informed consent for participation in the&#xD;
             study.&#xD;
&#xD;
          -  Male or Female, aged between 18 years and 70 years.&#xD;
&#xD;
          -  BMI: 25-45 kg/m2&#xD;
&#xD;
          -  HbA1C: 42-86mmol/mol&#xD;
&#xD;
          -  Normal renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Arm 1: SGLT2 inhibitors Volunteers taking insulin, glucagon-like peptide 1 analogues,&#xD;
        thiazolidinediones, or dipeptidyl peptidase IV inhibitors&#xD;
&#xD;
        Arm 2: metformin Volunteers taking insulin, glucagon-like peptide 1 analogues,&#xD;
        thiazolidinediones, SGLT2 inhibitors, metformin or dipeptidyl peptidase IV inhibitors&#xD;
&#xD;
        Both arms&#xD;
&#xD;
          -  Age &lt;18 or &gt;70 years&#xD;
&#xD;
          -  Body mass index &lt;25 or &gt;45kg/m2&#xD;
&#xD;
          -  A blood haemoglobin &lt;120mg/dL&#xD;
&#xD;
          -  History of alcoholism or a greater than recommended alcohol intake (Recommendations &gt;&#xD;
             21 drinks on average per week in men and &gt; 14 drinks on average per week in women)&#xD;
&#xD;
          -  Pregnant or nursing mothers&#xD;
&#xD;
          -  History of severe claustrophobia&#xD;
&#xD;
          -  Presence of metallic implants, pacemaker&#xD;
&#xD;
          -  Haemorrhagic disorders&#xD;
&#xD;
          -  Anticoagulant treatment&#xD;
&#xD;
          -  History of albumin allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy W Tomlinson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oxford</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

